Patrick Y Wen, MD
Alliance for Clinical Trials in Oncology · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patrick Y Wen, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:10 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07215910 · Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerAlliance for Clinical Trials in Oncology · recruiting · Astrocytoma, IDH-Mutant, Grade 3 · study chair
- Ph1NCT01339039 · Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade GliomaPatrick Y. Wen, MD · terminated · High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA) · principal investigator
- Ph2NCT01249105 · MK-2206 for Recurrent Malignant GliomaDana-Farber Cancer Institute · withdrawn · Malignant Glioma · principal investigator
- Ph2NCT00859040 · Monthly SOM230C for Recurrent or Progressive MeningiomaPatrick Y. Wen, MD · completed · Meningioma · principal investigator
- Ph1/Ph2NCT00859222 · LBH589 and Bevacizumab in Patients With Recurrent High Grade GliomaPatrick Y. Wen, MD · completed · Malignant Glioma · principal investigator
- Ph1/Ph2NCT00441142 · Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain TumorsPatrick Y. Wen, MD · completed · Glioblastoma Multiforme, Gliosarcoma · principal investigator
- Ph2NCT00165477 · Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeDana-Farber Cancer Institute · completed · Glioblastoma, Gliosarcoma, Malignant Gliomas · principal investigator
- Ph2NCT00047281 · Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant GliomaDana-Farber Cancer Institute · completed · Brain and Central Nervous System Tumors · study chair
- Ph2NCT00047294 · Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeDana-Farber Cancer Institute · completed · Brain and Central Nervous System Tumors · study chair
- Ph1/Ph2NCT00010049 · Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Brain and Central Nervous System Tumors · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00047281, NCT00047294
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in glioma.